Regeneron Pharmaceuticals, Inc. and CytomX Therapeutics, Inc. have announced a strategic research collaboration within the field of conditionally activated bispecific therapeutics for the ...

Fresh from claiming its first bispecific ... include Regeneron's odronextamab, Genmab/AbbVie's epcoritamab, and Roche's mosunetuzumab and glofitamab. Turning to the CD28 programme, the company ...

Rondo Therapeutics Presents Preclinical Data at ASCO GU for its Novel CD28 x Nectin-4 Costimulatory Bispecific Antibody for Advanced Bladder Cancer - Company plans to initiate a Phase 1/b trial in ...

Regeneron also resubmitted the BLA for odronextamab, a bispecific antibody targeting CD20 and CD3, in R/R follicular lymphoma, to the FDA. The EC also approved Kevzara (sarilumab) for the ...

“CD28 co-stimulatory bispecific antibodies are designed to boost T cell-mediated tumor killing and overcome T cell exhaustion in the solid tumor microenvironment. In preclinical ...